定义自体造血细胞移植复发后用于新型疗法的霍奇金淋巴瘤人群。 - Suppr

Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant.

作者信息

Arai Sally, Fanale Michelle, DeVos Sven, Engert Andreas, Illidge Tim, Borchmann Peter, Younes Anas, Morschhauser Franck, McMillan Alex, Horning Sandra J

机构信息

Stanford University , Stanford, CA , USA.

出版信息

Leuk Lymphoma. 2013 Nov;54(11):2531-3. doi: 10.3109/10428194.2013.798868. Epub 2013 Jun 5.

DOI:10.3109/10428194.2013.798868

PMID:23617324

Abstract

摘要

相似文献

Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant.定义自体造血细胞移植复发后用于新型疗法的霍奇金淋巴瘤人群。

Leuk Lymphoma. 2013 Nov;54(11):2531-3. doi: 10.3109/10428194.2013.798868. Epub 2013 Jun 5.

Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.单倍体或串联自体干细胞移植治疗首次复发或难治性霍奇金淋巴瘤：LYSA/SFGM-TC研究组前瞻性H96试验的10年随访

Haematologica. 2016 Apr;101(4):474-81. doi: 10.3324/haematol.2015.136408. Epub 2015 Dec 31.

Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplant.自体干细胞移植后复发或进展的霍奇金淋巴瘤患者的结局及危险因素

Leuk Lymphoma. 2014 Aug;55(8):1922-4. doi: 10.3109/10428194.2013.854888. Epub 2014 Jan 28.

The role of hematopoietic stem cell transplantation in advanced Hodgkin Lymphoma.造血干细胞移植在晚期霍奇金淋巴瘤中的作用。

Transfus Apher Sci. 2007 Aug;37(1):49-56. doi: 10.1016/j.transci.2007.04.005. Epub 2007 Aug 22.

Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway.挪威成人难治性或复发性霍奇金淋巴瘤自体干细胞移植大剂量治疗后的条件生存和超额死亡率

Haematologica. 2015 Jun;100(6):e240-3. doi: 10.3324/haematol.2014.119214. Epub 2015 Feb 14.

The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.造血干细胞移植治疗复发难治性霍奇金淋巴瘤的作用。

Am J Hematol. 2015 Feb;90(2):132-8. doi: 10.1002/ajh.23897. Epub 2014 Nov 24.

Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning.用于治疗复发/难治性非霍奇金淋巴瘤和霍奇金淋巴瘤成人患者的自体干细胞移植前的新型方案：替代BEAM预处理方案。

Leuk Lymphoma. 2016 Nov;57(11):2499-509. doi: 10.1080/10428194.2016.1185785. Epub 2016 May 31.

Mortality patterns among recipients of autologous hematopoietic stem cell transplantation for lymphoma and myeloma in the past three decades.过去三十年中淋巴瘤和骨髓瘤自体造血干细胞移植受者的死亡率模式。

Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):409-415.e1. doi: 10.1016/j.clml.2015.02.024. Epub 2015 Mar 5.

Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).首次复发或第二次缓解期霍奇金病的自体移植：来自自体血液和骨髓移植登记处（ABMTR）的报告

Bone Marrow Transplant. 2001 Feb;27(4):387-96. doi: 10.1038/sj.bmt.1702796.

Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT?自体造血干细胞移植（SCT）后复发的所有霍奇金淋巴瘤患者是否都应考虑异体 SCT？

Blood Adv. 2018 Apr 10;2(7):817-820. doi: 10.1182/bloodadvances.2017011122.

引用本文的文献

Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma: A systematic review and meta-analysis.复发/难治性霍奇金淋巴瘤自体干细胞移植后使用本妥昔单抗进行巩固治疗的真实世界结果：一项系统评价和荟萃分析。

Bone Marrow Transplant. 2025 Apr 8. doi: 10.1038/s41409-025-02557-7.

The validation of advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI) in Turkish patients with classical Hodgkin lymphoma.晚期霍奇金淋巴瘤国际预后指数（A-HIPI）在土耳其经典型霍奇金淋巴瘤患者中的验证

Ann Hematol. 2025 Mar;104(3):1765-1775. doi: 10.1007/s00277-025-06292-3. Epub 2025 Mar 12.

When should we use it? The role of brentuximab vedotin in 2024.我们应该何时使用它？2024年本妥昔单抗的作用。

Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):511-516. doi: 10.1182/hematology.2024000668.

Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China.在中国，与传统化疗相比，本妥昔单抗治疗复发或难治性经典型霍奇金淋巴瘤的成本效益分析。

Health Econ Rev. 2024 Jun 6;14(1):38. doi: 10.1186/s13561-024-00514-6.

Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy.免疫治疗时代复发性/难治性经典型霍奇金淋巴瘤的治疗优化

Cancers (Basel). 2023 Sep 11;15(18):4509. doi: 10.3390/cancers15184509.

Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era.自体造血干细胞移植后进展的 cHL 患者的总生存：新型药物时代的结果。

Blood Adv. 2023 Dec 12;7(23):7295-7303. doi: 10.1182/bloodadvances.2023011205.

Predictive Risk Score for Acute Kidney Injury in Hematopoietic Stem Cell Transplant.造血干细胞移植中急性肾损伤的预测风险评分

Cancers (Basel). 2023 Jul 22;15(14):3720. doi: 10.3390/cancers15143720.

Classical Hodgkin Lymphoma: From Past to Future-A Comprehensive Review of Pathophysiology and Therapeutic Advances.经典型霍奇金淋巴瘤：从过去到未来——发病机制和治疗进展的综合综述。

Int J Mol Sci. 2023 Jun 13;24(12):10095. doi: 10.3390/ijms241210095.

Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant.自体干细胞移植后复发的经典型霍奇金淋巴瘤患者的预后

Hemasphere. 2023 Apr 4;7(4):e869. doi: 10.1097/HS9.0000000000000869. eCollection 2023 Apr.

Advances in the treatment of Hodgkin lymphoma: Current and future approaches.霍奇金淋巴瘤治疗进展：当前与未来的方法

Front Oncol. 2023 Mar 3;13:1067289. doi: 10.3389/fonc.2023.1067289. eCollection 2023.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献